Meeting NewsVideo

VIDEO: CD19–directed CAR T cells shows promise in advanced lymphomas

CHICAGO — Treatment with JCAR017 showed promise in patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma, according to the phase 1 TRANSCEND NHL trial presented at the ASCO Annual Meeting.

Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, and colleagues evaluated the safety and efficacy of JCAR017 (Juno Therapeutics) in 28 patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma or mantle cell lymphoma.

Patients demonstrated high complete response rates. Further, toxicities appeared manageable and occurred at rates lower than those reported for other CD19–directed CAR T-cell products.

“Though our follow-up is still relatively brief, many of these remissions are proving durable and will hopefully prove curative,” Abramson said.

Next, Abramson and colleagues plan to expand the study into a pivotal population in hopes of FDA approval.

“We’re very optimistic that moving forward, we’ll see very exciting results in an ongoing way that hopefully lead this drug to being available for patients worldwide,” he added. – by Kristie L. Kahl

Disclosure: Abramson reports consultant/advisory roles with AbbVie, Celgene, Genentech/Roche, Gilead Sciences, Incyte, Kite Pharma and Seattle Genetics; and research funding from Celgene, Genentech, Millennium and Seattle Genetics.

CHICAGO — Treatment with JCAR017 showed promise in patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma, according to the phase 1 TRANSCEND NHL trial presented at the ASCO Annual Meeting.

Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, and colleagues evaluated the safety and efficacy of JCAR017 (Juno Therapeutics) in 28 patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma or mantle cell lymphoma.

Patients demonstrated high complete response rates. Further, toxicities appeared manageable and occurred at rates lower than those reported for other CD19–directed CAR T-cell products.

“Though our follow-up is still relatively brief, many of these remissions are proving durable and will hopefully prove curative,” Abramson said.

Next, Abramson and colleagues plan to expand the study into a pivotal population in hopes of FDA approval.

“We’re very optimistic that moving forward, we’ll see very exciting results in an ongoing way that hopefully lead this drug to being available for patients worldwide,” he added. – by Kristie L. Kahl

Disclosure: Abramson reports consultant/advisory roles with AbbVie, Celgene, Genentech/Roche, Gilead Sciences, Incyte, Kite Pharma and Seattle Genetics; and research funding from Celgene, Genentech, Millennium and Seattle Genetics.

    See more from ASCO Annual Meeting